PharmaDiagnostics (Brussels) a development-stage diagnostic services company focused on drug discovery screening technology based on localised surface plasmon resonance and noble metal nanoparticles in solution, closed a $3.7M Series B financing. Participants include Capital-E.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.